* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Days Payable Chart
SHSE:688166 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's Days Payable falls into.
Brightgene Bio-medical Technology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Days Payable of 107.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is 15% below median its historical median of 126.29. Over the past decade, Brightgene Bio-medical Technology Co's Days Payable has ranged from 68.41 to 225.07. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #352 out of 701 companies in the Biotechnology industry, placing it in the top 50.2%.
Is Brightgene Bio-medical Technology Co's Days Payable too high?
Brightgene Bio-medical Technology Co's current Days Payable of 107.21 is 15% below median its 10-year median of 126.29. Over the past 10 years, this metric has ranged from a low of 68.41 to a high of 225.07. The Biotechnology industry median Days Payable is 112.84. Brightgene Bio-medical Technology Co's value of 107.21 is 5% below this industry median. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #352 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #352 out of 701 companies for Days Payable. This places Brightgene Bio-medical Technology Co in the lower half of its industry. The industry median Days Payable is 112.84. Brightgene Bio-medical Technology Co's value of 107.21 is 5% below this benchmark. Historically, Brightgene Bio-medical Technology Co's own Days Payable has ranged from 68.41 to 225.07 over the past decade. While the company's 10-year median is 126.29 vs. the industry median of 112.84, Brightgene Bio-medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brightgene Bio-medical Technology Co's current Days Payable of 107.21 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Brightgene Bio-medical Technology Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brightgene Bio-medical Technology Co's current Days Payable is 107.21, which is 15% below median its own 10-year median of 126.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Days Payable is 107.21, which is 15% below median its 10-year median of 126.29 and 5% below the Biotechnology industry median of 112.84. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Days Payable is 107.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Days Payable: 107.21 (15% below median its 10-year median of 126.29)
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
Industry Position: 5% below the Biotechnology median (#352 of 701)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
